Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2025-12-25 @ 2:30 AM
NCT ID:
NCT06602934
Eligibility Criteria:
Inclusion Criteria:
Group A (patients with acute cardiac disease)
* Male or female
* Age ≥ 40years old
* Hospitalized for acute coronary syndrome for less than 7 days.
* Informed consent from the patient
* Person insured under a health insurance scheme
Group B (patients with chronic cardiovascular disease)
* Male or female,
* Age ≥ 40 years old
* Undergoing coronary artery by-pass surgery
* Hospitalized in intensive care unit for \> 12 hours
* Informed consent from the patient
* Person insured under a health insurance scheme
Group C (patients at risk of CVRD without chronic cardiovascular disease)
* Male or female,
* Age ≥ 40 years old
* Familial high levels of cholesterol or triglycerides
* With no personal history of CVRD, with a recent negative cardiac exercise test (last test inferior to 12 months)
* Follow-up for lipid abnormalities at high risk of CVRD events
* Informed consent from the patient
* Person insured under a health insurance scheme
Group D (patients with HAP)
* Male or female
* Age ≥ 40years old
* With one or more risk factors for CVD among:
smoking, abnormal lipidic levels, high blood pressure, obesity, diabetes mellitus, chronic kidney disease
* Cured from mechanically ventilated HAP during the current hospitalization
* Informed consent from the patient or relatives
* Person insured under a health insurance scheme
Exclusion Criteria:
* o Groups A, B, C and D
* Age \>80 years old
* Immunosuppression pre-existing to the index hospitalisation, defined as lymphopenia \< 500 elements/mm3, haematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug.
* Pregnant women, breastfeeding women.
* Adults under guardianship or trusteeship.
* Low probability of survival at day 28.
o Groups A, B, C
* Community-acquired pneumonia or Hospital-acquired pneumonia within the last year.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
40 Years
Maximum Age:
80 Years
Study:
NCT06602934
Study Brief:
Protocol Section:
NCT06602934